Tran 2004 VNM.

Methods	Trial design: An open label RCT Follow‐up: Malaria film on days 0, 2, and 7. Participants followed up to day 56 but further details not described Adverse event monitoring: Not described
Participants	Number of participants: 243 Inclusion criteria: Age > 2 yrs, microscopically confirmed uncomplicated P. falciparum malaria Exclusion criteria: Pregnancy, evidence of organ dysfunction, unable to tolerate oral medication, unable to return for follow‐up, resident in Dac O for > 2 years
Interventions	1. DHA‐P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin) Adults: 2 tablets at 0, 6, 24, and 48 hrs Children < 15 yrs: 1 tablet at 0, 6, 24, and 48 hrs 2. Artesunate plus mefloquine, loose combination (artesunate: Guilin, Lariam: Hoffman‐La Roche) AS 4 mg/kg once daily for 3 days MQ 25 mg base/kg as 2 divided doses 6 hrs apart on day 3
Outcomes	Parasitological failure at days 42 and 28, PCR‐adjusted and PCR‐unadjusted Adverse events Not included in this review: Fever clearance Parasite clearance
Notes	Country: Vietnam Setting: Health station Transmission: Low and seasonal Resistance: Multiple‐drug resistance Dates: Nov 2001 to Mar 2002 Funding: Wellcome Trust of Great Britain
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Patients were randomly allocated one of three treatments in a ratio of 2:2:1". No further details given.
Allocation concealment (selection bias)	Unclear risk	"Drugs were kept in identically numbered opaque envelopes". No further details.
Blinding for microscopy outcomes (performance bias and detection bias)	Unclear risk	No comment on blinding of laboratory staff.
Blinding for adverse events (performance and detection bias)	High risk	An open label trial.
Incomplete outcome data (attrition bias) All outcomes	Low risk	"There were no losses to follow‐up".
Selective reporting (reporting bias)	Unclear risk	It is unclear from the paper whether it is only clinical failure that is being reported.
Other bias	Low risk	No other sources of bias identified.